viewPreveCeutical Medical Inc.

PreveCeutical encouraged by gel spray nasal delivery of cannabis-based treatments

The Vancouver-based company is working on formulations for the treatment of epilepsy, anxiety and depression.

Nasal spray
PreveCeutical says its gel sprays are superior to conventional liquid sprays in delivering formulations into the upper nasal cavity.

PreveCeutical Medical Inc (CSE:PREV, OTCMKTS:PRVCF) said Monday that it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments of epilepsy, anxiety and depression.

The gel spray is superior to conventional liquid sprays in delivering formulations into the upper nasal cavity, the Vancouver-based company said in a press release. PreveCeutical’s Sol-gels are delivered by using a device known as the So-gel Applicator.

READ: PreveCeutical Medical joins forces with Asterion Cannabis to develop CBD products

"This is an important development for PreveCeutical, having demonstrated that its engineered Sol-gels and applicator device achieve delivery and retention directly at target tissue high in the nasal cavity,” Dr. Harendra Parekh, chief research officer, said in a statement.

The company said in August that it is developing a cannabinoid formulation for the treatment of patient anxiety.

In September, PreveCeutical struck a deal with Asterion Cannabis Inc to develop cannabis-based medical products.

Shares eased 5.26% to $0.09 in Toronto.

Quick facts: PreveCeutical Medical Inc.

Price: 0.04 CAD

Market: CSE
Market Cap: $19.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 07/23/2020

2 min read